Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022

– IONIS-FB-LRx achieved a 44% mean reduction in proteinuria in patients treated for 6 months – Roche to advance IONIS-FB-LRx into Phase 3 development in H1 2023 CARLSBAD, Calif., Nov. 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology's (ASN) Kidney Week 2022.

The release as fetched from its publisher. ionis.com ↗